Which specific molecular targets downstream of transcription factors like SREBP2 are druggable for cell-type selective interventions?

The feasibility assessment identified that most proposed targets (SREBP2, transcriptional regulators) are non-druggable. The critical gap is identifying which downstream effector proteins or pathways could be pharmacologically modulated with cell-type specificity.

Source: Debate session sess_SDA-2026-04-04-analysis_sea_ad_001 (Analysis: SDA-2026-04-04-analysis_sea_ad_001)